( SAN CARLOS Calif. June 05 2007 /PRN...)Nuvelo Announces Publication of Preclinical Study Results,Demonstrating the Potential of NTB-A as a New Target for Leukemia,and Lymphomas,Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Nuvelo Announces Publication of Preclinical Study Results,Demonstrating the Potential of NTB-A as a New Target for Leukemia,and Lymphomas
SAN CARLOS, Calif., June 05, 2007 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced the publication of data from a preclinical study of novel monoclonal antibodies against the cell-surface protein NTB-A. The data demonstrate that NTB-A is a potential new target for immunotherapy of B-cell malignancies including leukemia and lymphomas. The study, entitled "The lymphoid cell surface receptor NTB-A: a novel monoclonal antibody target for leukemia and lymphoma therapeutics," appears in the May issue of British Journal of Haematology.
Leukemia and lymphomas are malignancies of lymphoid cells. Monoclonal antibodies, in addition to chemotherapy, have been shown to be effective in eliminating lymphocytes in leukemia and lymphoma patients (1,2,3,4). However, a significant number of patients relapse after initial responses and eventually become resistant to existing therapies.
"The development of new antibody therapeutics is an important area of study as leukemia and lymphoma patients need more treatment options. This study not only lays the scientific foundation for continued NTB-A target and antibody development, but it also validates the focus of our cancer antibody research and moves us closer to identifying a lead candidate from this program," said Walter Funk, Ph.D., vice president of research for Nuvelo. "In addition to pursuing the NTB-A target, we are also studying other monoclonal antibody targets in blood cell malignancies and solid tumor cancers, and have established collaborations with leading clinical centers that support our ongoing preclinical program."
NTB-A is a CD2-related cell surface protein expressed primarily
on lymphoid cells including B-lymphocytes from chronic lymphocytic
leukemia (CLL) and lymphoma patients. Nuvelo has generated a series
of monoclonal antibodies against NTB-A and assessed their
therapeutic potential for treating CLL and lymphoma through
preclinical tri
'"/>
Related medicine technology :
1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
4. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
5. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:11/20/2009)...swire/ -- Reportlinker.com announces that a new ma.... ,, Pipettes & Pipettors - A Global Marke.../p0164373/Pipettes--Pipettors---A-Global-Market-Pe...m=pr&utm_campaign=prnewswire ,, Pipettes ...ny research laboratory. Large-scale applications i...
(Date:11/20/2009)...ov. 20 Boston Scientific...t has received 510(k) clearance from the U.S. Food...l to market its WallFlex® Fully Covered Esoph...eal strictures (obstructions) caused by tumors in ...eal cancer. ,, (Photo: http://www.newscom.co...
(Date:11/20/2009)...ewswire-FirstCall/ -- Smith & Nephew ( SNN, LS...e the signing of a technology development contract... may lead to the creation of a fracture fixation s...he limbs of soldiers who sustain battlefield injur...h Projects Agency (DARPA), the central research an...
Breaking Medicine Technology:Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4ProDrive Systems Announces Exclusive Distribution Agreement with Patterson Dental Canada 56087 1ProDrive Systems Announces Exclusive Distribution Agreement with Patterson Dental Canada 56087 2Chindex International Announces September Investor Conferences Participation 56083 1Chindex International Announces September Investor Conferences Participation 56083 2Abbott to Acquire Visiogen Expanding Vision Care Portfolio 56078 1Abbott to Acquire Visiogen Expanding Vision Care Portfolio 56078 2Abbott to Acquire Visiogen Expanding Vision Care Portfolio 56078 3Abbott to Acquire Visiogen Expanding Vision Care Portfolio 56078 4Abbott to Acquire Visiogen Expanding Vision Care Portfolio 56078 5...tho-McNeil Neurologics, a,division of Ortho-McNeil...at the U.S. Food and Drug Administration (FDA) has...iramate), based on studies submitted in,response t...use of TOPAMAX,in pediatric patients aged 1 to 24 ...to granting pediatric exclusivity, the FDA is cont...
...4 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) a...ase 3 clinical trial with AZ-004 (Staccato(R) loxa...eing developed for the treatment,of acute agitatio...er.,Alexza believes the novel, non-invasive nature...ng from inhaled loxapine administration via the,St...
Other Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6(Date:11/20/2009)... supply, study finds , , FRIDAY, Nov. 20...f prescription drugs is up to one-third cheaper th...tudy. , U.S. researchers analyzed 26,852 prescr..., and found that patients who bought a three-month...rage 29 percent in out-of-pocket costs. After the ...
(Date:11/20/2009)...ed to continue, CDC says, , , FRIDAY, N...d States are seeing declines in H1N1 swine flu act...while the disease remains widespread in 43 states,.... , "We are beginning to see some declines in i... still a lot of influenza everywhere," Dr. Anne Sc...
(Date:11/20/2009)...ased food insecurity as many face problem of hunge...- Project Bread, the state,s leading anti-hunger o...nual status report on hunger in the Commonwealth. ...aused by high unemployment, point to 554,000 peopl... insecurity has found its way into middle class su...
(Date:11/20/2009)... Omnicell, Inc. (Nasdaq:... acute healthcare facilities, announced today the ...fray Healthcare Conference at the New York Palace... Randall A. Lipps, founder, chairman, president &a..., Date: Tuesday, December 1, 2009 ,, Time: ...
(Date:11/20/2009)...wswire-USNewswire/ -- The Louisiana Association ...ans could experience higher health care premiums a...by Congress should become law. ,, According to ...siana health plans have supported comprehensive he...al debate. Our plans have offered significant cha...
Breaking Medicine News(10 mins):Health News:Three-Month Supply Lowers Drug Costs 2Health News:Swine Flu Declining in Some Parts of U.S. 2Health News:Swine Flu Declining in Some Parts of U.S. 3Health News:554,000 in Massachusetts Struggle to Put Food on the Table 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 3Health News:554,000 in Massachusetts Struggle to Put Food on the Table 4Health News:Omnicell to Present at Piper Jaffray Healthcare Conference 2Health News:Congressional Health Care Reform Proposals Would Make Health Care More Expensive, Reduce Benefits for Louisianians 2[0] Three-Month Supply Lowers Drug Costs[0] Swine Flu Declining in Some Parts of U.S.[0] 554,000 in Massachusetts Struggle to Put Food on the Table[0] Omnicell to Present at Piper Jaffray Healthcare Conference[0] Congressional Health Care Reform Proposals Would Make Health Care More Expensive, Reduce Benefits for Louisianians
...shows amount in outer hair cell membranes affects ...ount of cholesterol in the outer hair cell membran... study concludes. , "We,ve known for a long time t...ing," senior author Dr. William Brownell, a profes...
...ars of follow-up, older women taking the newer dru...c. 14 (HealthDay News) -- The aromatase inhibitor ...d tamoxifen when it comes to preventing recurrence... a benefit, researchers said. , "It has been very...
...ber 14, 2007 A new review article from the journa...rug used to treat lymphoma, is now becoming used b...iseases. , Originally developed as the standard ...n dermatology and found that it successfully treat...
...c. 14 Veridex, LLC, a,Johnson & Johnson company, ...d the GeneSearch(TM) Breast Lymph Node (BLN) Assay..., In the December 24th issue of the magazine, ava... say, "doctors can,accurately test the sentinel no...
...ec. 14 The 10th Annual Customer,Experience Confer...ience,",sponsored by Best Practices, LLC,s Global ...ton Hotel in Phoenix, Ariz., Feb. 25-27, 2008. Thi...tition., Download "Using Quality to Improve the C...
... Combines Personal Responsibility and Public,Dolla...tt today announced the approval of a Medicaid waiv...nt an innovative health care proposal giving,appro...g applications for the new health care coverage, c...
Other Medicine News:Health News:Study Finds Cholesterol Fine-Tunes Hearing 2Health News:Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay 2Health News:Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay 3Health News:TIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007 2Health News:TIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007 3Health News:TIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007 4Health News:Reserve 2008 Budget for Using Quality to Improve the Customer Experience 2Health News:HHS Approves Medicaid Waiver to Create New Indiana Health Plan for Uninsured Hoosiers 2Study Finds Cholesterol Fine-Tunes HearingArimidex Beats Tamoxifen in Keeping Breast Cancer at BayLymphoma drug used to treat skin disordersTIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007Reserve 2008 Budget for Using Quality to Improve the Customer ExperienceHHS Approves Medicaid Waiver to Create New Indiana Health Plan for Uninsured Hoosiers
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |